Literature DB >> 7762059

The effect of immunosuppressive drugs on quality of life after renal transplantation.

L B Hilbrands1, A J Hoitsma, R A Koene.   

Abstract

This prospective, randomized study investigates the effect of two immunosuppressive treatment regimens on quality of life after renal transplantation. At 3 months after transplantation, patients treated with cyclosporine (CsA) and prednisone (Pred) were allocated to either withdrawal of Pred (n = 60) or to conversion of CsA to azathioprine (Aza) (Aza-Pred, n = 60). Quality of life was evaluated just before randomization, and at 6 and 12 months after transplantation using the Sickness Impact Profile (SIP), the Affect Balance Scale (ABS), the Center for Epidemiological Studies Depression Scale (CES-D), measures of satisfaction with several domains of life experience, and a population-specific physical symptoms questionnaire. In both groups, the overall SIP score as well as the scores on its physical and psychosocial dimensions improved continuously after transplantation, reaching levels that are comparable to those found in the general population. The occurrence of acute or chronic rejection had a significantly negative effect on SIP and CES-D scores. Intention-to-treat analysis showed no differences between groups for scores on SIP, ABS, CES-D, and satisfaction measures. Exclusion of 41 patients who did not strictly adhere to their originally designated therapy showed a tendency for better psychosocial SIP scores in CsA patients (P = 0.05), which mainly resulted from a difference on the category of social interaction (P = 0.01). This difference occurred despite a similar rejection rate and worse renal function in CsA-treated patients. Shortly after steroid withdrawal, a high proportion of CsA patients complained of stiff or painful muscles (CsA: 74%, Aza-Pred: 36%; P = 0.002). Our data indicate that if successfully completed, CsA monotherapy from 3 months after transplantation may lead to a higher degree of psychosocial well-being as compared with conversion from CsA-Pred to Aza-Pred. It seems likely that this advantage is related to the withdrawal of Pred.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762059

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Authors:  Krishna M Karpe; Girish S Talaulikar; Giles D Walters
Journal:  Cochrane Database Syst Rev       Date:  2017-07-21

Review 2.  Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.

Authors:  M Behrend
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.

Authors:  Lisa Mellon; Frank Doyle; Anne Hickey; Kenneth D Ward; Declan G de Freitas; P Aiden McCormick; Oisin O'Connell; Peter Conlon
Journal:  Cochrane Database Syst Rev       Date:  2022-09-12

4.  The results of 1009 kidney transplantations performed in Hungary.

Authors:  F Perner; J Járay; F Alföldy; M Hídvégi; K Darvas; D Görög; A Tóth; T Gondos; E Toronyi; G Petrányi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 5.  New trends on health related quality of life assessment in end-stage renal disease patients.

Authors:  Pablo Rebollo; Francisco Ortega
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.